CIMAvax-EGF: Cuba's Innovative Approach to Lung Cancer Immunotherapy

CIMAvax-EGF is one of Cuba's most significant medical biotechnology innovations. Developed by the Center of Molecular Immunology (CIM) in Havana, it is a therapeutic vaccine — meaning it is designed to treat disease that is already present, not to prevent it — for advanced non-small cell lung cancer.

The vaccine works through a unique mechanism: it trains the patient's immune system to produce antibodies against Epidermal Growth Factor (EGF), a protein that tumors rely on to grow and spread. By removing this protein from the bloodstream, the vaccine helps 'starve' the cancer cells of a key growth signal, slowing tumor growth and extending patient survival. CIMAvax-EGF is typically given as maintenance therapy — treatment that continues after standard first-line therapy is completed, to help keep the disease controlled.

The vaccine has completed Phase III trials in Cuba and is now undergoing international clinical trials, including in the United States through a partnership with Roswell Park Comprehensive Cancer Center. It is part of a broader Cuban approach that combines biotechnology innovation with comprehensive patient care, given under the supervision of experienced oncology teams in specialized clinical facilities with full supportive care and monitoring.